# EDGAR Filing Document

**Accession Number:** 0001213037
**File Stem:** 0002110286-26-000003
**Filing Date:** 2026-2
**Character Count:** 5734
**Document Hash:** e115754b20c8cb24a7df9a35af592db7
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0002110286-26-000003.hdr.sgml**: 20260209

**ACCESSION NUMBER**: 0002110286-26-000003

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260127

**FILED AS OF DATE**: 20260209

**DATE AS OF CHANGE**: 20260209

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Lindsay Brigitte Ute
- **CENTRAL INDEX KEY:** 0002110286

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-35558
- **FILM NUMBER:** 26611367

**MAIL ADDRESS:**
- **STREET 1:** 11055 FLINTKOTE AVENUE
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Cardiff Oncology, Inc.
- **CENTRAL INDEX KEY:** 0001213037
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 272004382
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 11055 FLINTKOTE AVENUE
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121
- **BUSINESS PHONE:** 858-952-7570

**MAIL ADDRESS:**
- **STREET 1:** 11055 FLINTKOTE AVENUE
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Trovagene, Inc.
- **DATE OF NAME CHANGE:** 20130304

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** TrovaGene Inc.
- **DATE OF NAME CHANGE:** 20110830

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** XENOMICS INC
- **DATE OF NAME CHANGE:** 20040719

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Lindsay Brigitte Ute<br><sub>(Last) (First) (Middle)</sub><br>11055 FLINTKOTE AVENUE<br><sub>(Street)</sub><br>SAN DIEGO, CA 92121<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>Cardiff Oncology, Inc. [ CRDF ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2026-01-27 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [ ] 10% Owner<br>[X] Officer (give title below)   [ ] Other (specify below)<br>_Chief Accounting Officer_ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |
| Common Stock | 27431 | D |  |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Stock Options | <sup>(1)</sup> | 2028-01-23 | Common Stock | 1753 | $21.60 | D |  |
| Stock Options | <sup>(2)</sup> | 2029-06-20 | Common Stock | 89469 | $2.48 | D |  |
| Stock Options | <sup>(3)</sup> | 2030-06-17 | Common Stock | 96192 | $2.60 | D |  |
| Stock Options | <sup>(4)</sup> | 2031-06-10 | Common Stock | 154704 | $7.98 | D |  |
| Stock Options | <sup>(5)</sup> | 2032-03-09 | Common Stock | 131568 | $2.50 | D |  |
| Stock Options | <sup>(6)</sup> | 2033-03-15 | Common Stock | 90288 | $1.72 | D |  |
| Stock Options | <sup>(7)</sup> | 2034-03-17 | Common Stock | 95040 | $3.51 | D |  |
| Stock Options | <sup>(8)</sup> | 2035-03-11 | Common Stock | 166320 | $3.58 | D |  |

---

### Footnotes:

(1) 1,198 vested on January 23, 2018. 185 vested on January 23, 2019, 2020 and 2021.

(2) 29,823 vested on June 20, 2020, 2021 and 2022.

(3) 32,064 vested on June 17, 2021, 2022 and 2023.

(4) 38,676 vested on June 10, 2022 and 3,223 vested monthly for 36 months thereafter.

(5) 32,892 vested on March 9, 2023 and 2,741 vest monthly for 36 months thereafter.

(6) 22,572 vested on March 15, 2024 and 1,881 vest monthly for 36 months thereafter.

(7) 23,760 vested on March 7, 2025 and 1,980 vest monthly for 36 months thereafter.

(8) 41,580 vest on March 11, 2026 and 3,465 vest monthly for 36 months thereafter.

**Signature:** /s/ Brigitte Lindsay  
**Date:** 2026-02-09

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**